via Georgia State University
Scientists have found an off-patent drug that may prevent Covid-19 – and protect against future variants of the virus – using a mix of ‘mini-organs’, donor organs, animal studies and patients.
The research, involving Newcastle University’s Professor Andrew Fisher, published today in Nature, showed that an existing drug used to treat a type of liver disease is able to ‘lock’ the doorway by which SARS-CoV-2 enters our cells, a receptor on the cell surface known as ACE2.
In addition, because this drug targets the host cells and not the virus, it should protect against future new variants of the virus as well as other coronaviruses that might emerge.
If confirmed in larger clinical trials, this could provide a vital drug for protecting those individuals for whom vaccines are ineffective or inaccessible as well as individuals at increased risk of infection.
Dr Fotios Sampaziotis, from the Wellcome-MRC Cambridge Stem Cell Institute at the University of Cambridge and Addenbrooke’s Hospital, led the research in collaboration with Professor Ludovic Vallier from the Berlin Institute of Health at Charité.
Dr Sampaziotis said: “Vaccines protect us by boosting our immune system so that it can recognise the virus and clear it, or at least weaken it. But vaccines don’t work for everyone – for example patients with a weak immune system – and not everyone have access to them. Also, the virus can mutate to new vaccine-resistant variants.
“We’re interested in finding alternative ways to protect us from SARS-CoV-2 infection that are not dependent on the immune system and could complement vaccination. We’ve discovered a way to close the door to the virus, preventing it from getting into our cells in the first place and protecting us from infection.”
From mini-organs and animals …
Dr Sampaziotis had previously been working with organoids – ‘mini-bile ducts’ – to study diseases of the bile ducts. Organoids are clusters of cells that can grow and proliferate in culture, taking on a 3D structure that has the same functions as the part of the organ being studied.
Using these, the researchers found – rather serendipitously – that a molecule known as FXR, which is present in large amounts in these bile duct organoids, directly regulates the viral ‘doorway’ ACE2, effectively opening and closing it. They went on to show that ursodeoxycholic acid (UDCA), an off-patent drug used to treat a form of liver disease known as primary biliary cholangitis, ‘turns down’ FXR and closes the ACE2 doorway.
In this new study, his team showed that they could use the same approach to close the ACE2 doorway in ‘mini-lungs’ and ‘mini-guts’ – representing the two main targets of SARS-CoV-2 – and prevent viral infection.
The next step was to show that the drug could prevent infection not only in lab-grown cells but also in living organisms. For this, they teamed by with Professor Andrew Owen from the University of Liverpool to show that the drug prevented infection in hamsters exposed to the virus, which are used as the ‘gold-standard’ model for pre-clinical testing of drugs against SARS-CoV-2. Importantly, the hamsters treated with UDCA were protected from the -new at the time- delta variant of the virus, which was -at least partially- resistant to existing vaccines.
Professor Owen said: “Although we will need properly-controlled randomised trials to confirm these findings, the data provide compelling evidence that UDCA could work as a drug to protect against Covid-19 and complement vaccination programmes, particularly in vulnerable population groups. As it targets the ACE2 receptor directly, we hope it may be more resilient to changes resulting from the evolution of the SARS-CoV-2 spike, which result in rapid emergence of new variants.”
Next, the researchers worked with Professor Andrew Fisher from Newcastle University and Professor Chris Watson from Addenbrooke’s hospital to see if their findings in hamsters held true in human lungs exposed to the virus.
The team took a pair of donated lungs not suitable for transplantation, keeping them breathing outside the body with a ventilator and using a pump to circulate blood-like fluid through them to keep the organs functioning while they could be studied. One lung was given the drug, but both were exposed to SARS-CoV-2. Sure enough, the lung that received the drug did not become infected, while the other lung did.
Professor Fisher, Dean of Clinical Medicine and Professor of Respiratory Transplant Medicine at Newcastle University, said: “This is one of the first studies to test the effect of a drug in a whole human organ while it’s being perfused.
“This could prove important for organ transplantation – given the risks of passing on Covid-19 through transplanted organs, it could open up the possibility of treating organs with drugs to clear the virus before transplantation.”
… to people
Moving next to human volunteers, the Cambridge team collaborated with Professor Ansgar Lohse from the University Medical Centre Hamburg-Eppendorf in Germany.
Professor Lohse explained: “We recruited eight healthy volunteers to receive the drug. When we swabbed the noses of these volunteers, we found lower levels of ACE2, suggesting that the virus would have fewer opportunities to break into and infect their nasal cells – the main gateway for the virus”.
While it wasn’t possible to run a full-scale clinical trial, the researchers did the next best thing: looking at data on Covid-19 outcomes from two independent cohorts of patients, comparing those individuals who were already taking UDCA for their liver conditions against patients not receiving the drug. They found that patients receiving UDCA were less likely to develop severe Covid-19 and be hospitalised.
A safe, affordable variant-proof drug
First author and PhD candidate Teresa Brevini from the University of Cambridge said: “This unique study gave us the opportunity to do really translational science, using a laboratory finding to directly address a clinical need.
“Using almost every approach at our fingertips we showed that an existing drug shuts the door on the virus and can protect us from Covid-19. Importantly, because this drug works on our cells, it is not affected by mutations in the virus and should be effective even as new variants emerge.”
Dr Sampaziotis said the drug could be an affordable and effective way of protecting those for whom the Covid-19 vaccine is ineffective or inaccessible. “We have used UDCA in clinic for many years, so we know it’s safe and very well tolerated, which makes administering it to individuals with high Covid-19 risk straightforward.
“This tablet costs little, can be produced in large quantities fast and easily stored or shipped, which makes it easy to rapidly deploy during outbreaks – especially against vaccine-resistant variants, when it might be the only line of protection while waiting for new vaccines to be developed. We are optimistic that this drug could become an important weapon in our fight against Covid-19.”
Original Article: Off-patent liver disease drug could prevent COVID-19 infection
The Latest Updates from Bing News
Go deeper with Bing News on:
- Intercept's (ICPT) NDA for NASH Treatment Accepted By FDA
Intercept's (ICPT) new drug application (NDA) for obeticholic acid (OCA) for the treatment of nonalcoholic steatohepatitis gets accepted by the regulatory body in the United States.
- Hyperaggressive Seals Likely Poisoned With Acid Are Attacking Humans
A spate of attacks by seals around Cape Town in South Africa may be due to the marine mammals having been poisoned by domoic acid. The domoic acid, a toxin released during a red tide algal bloom ...
- Ursodeoxycholic Acid API Market 2023 Will See a Massive Rise in Revenues of 954.2 Million by 2028 With 11.8% CAGR| 109 Pages Report
The MarketWatch News Department was not involved in the creation of this content. The global Ursodeoxycholic Acid API market size is estimated to be worth USD 488.7 million in 2022 and is forecast ...
- Get Your Energy Levels Up With the Best Folic Acid Supplement
Folic acid is a water-soluble vitamin mainly found in leafy green vegetables, legumes, nuts, and fortified foods. Pregnant people need to take a folic acid supplement to prevent congenital ...
- Gestational Diabetes, Preeclampsia: Blood Test May Be Able to Detect Pregnancy Complications
Researchers say a simple blood test may be able to detect pregnancy complications such as gestational diabetes and preeclampsia, allowing treatments to begin earlier ...
Go deeper with Bing News on:
- UC San Diego: Host-Cell Factors Involved in COVID-19 Infections May Augur Improved Treatments
Researchers at University of California San Diego and UC Riverside have further elucidated the molecular pathway used by the SARS-CoV-2 virus to infect human lung cells, identifying a key host-cell ...
- Doorway Financial Announces New Financial Management Solutions for Institutional and Individual Clients
Wilmington, Delaware--(Newsfile Corp. - January 27, 2023) - Doorway Financial, an established global alternative investment manager with over 15 years of experience, is pleased to announce the ...
- Omicron RBD mutations increase ACE2 binding and reduce antibody sensitivity
The findings reveal that mutation-induced structural changes in the omicron RBD result in more efficient ACE2 binding. The study is currently available on the bioRxiv* preprint server. Soon after ...
- Host Cell Factors Open Door to Potential Novel Therapies for COVID-19
A new study advocates for drug development targeting host-cell factors, such as PCIF1 and TMPRSS2, to treat COVID-19.
- Researchers identify a key host-cell player in COVID-19 infections
The researchers found that PCIF1 promotes the stability of both ACE2 and TMPRSS2 mRNAs ... "Essentially, it's as if once SARS-CoV-2 has opened the door to a cell, PCIF1 helps keep the door ...